The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines initiative began in 2010 when a group of researchers and clinicians united to address the lack of formal guidance on the use of cancer immunotherapy.
Each consensus statement is developed by an expert subcommittee in a particular disease setting using the National Academy of Medicine’s (formerly Institute of Medicine) Standards for Developing Trustworthy Clinical Practice Guidelines as a model. One aspect of this systematic process is a 30-day open comment period allowing the general public to provide feedback on the current draft of the consensus statement prior to publication. SITC relies on this feedback to ensure the guidelines address all relevant issues and meet the goals of this initiative.
Please see below for available SITC Cancer Immunotherapy Guidelines open comment periods.
The number of Cancer Immunotherapy Guidelines published by SITC via the Journal for ImmunoTherapy of Cancer (JITC) continues to grow. Click the links below to view previously published guidelines in different disease states:
Click the following links to learn more about the leaders charged with creating the SITC Guidelines:
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com